• Home
  • News
  • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics
  1. home
  1. home
  2. Brainstorm Health

Brainstorm Health

Page 10 of 83

Nestle Aimmune Peanut Allergy Drug
Newsletters

Nestlé invests another $200 million in Aimmune’s peanut allergy drug

By Market Analyst
February 6, 2020
What Andreessen’s ‘Bio Fund III’ means for healthcare
Newsletters

What Andreessen’s ‘Bio Fund III’ means for healthcare

By Editorial Team
February 5, 2020
A vaccine that looked promising for HIV doesn’t work
Newsletters

A vaccine that looked promising for HIV doesn’t work

By Senior Editor
February 4, 2020
Vertex Pharmaceuticals Earnings 2019
Newsletters

Vertex CEO takes an earnings victory lap right before he exits

By Crypto Correspondent
January 31, 2020
Eli Lilly Earnings Diabetes Sales
Newsletters

Eli Lilly smashed Wall Street projections thanks to its diabetes drugs

By Research Team
January 30, 2020
Novartis Zolgensma Gene Therapy Sales
Newsletters

Why a drug that costs $2.1 million per dose is on a sales streak

By Research Team
January 29, 2020
Bloomberg Drug Prices
Newsletters

One drug, one patent?

By Investment Desk
January 29, 2020
Kobe Bryant Death Science of Grief
Newsletters

Kobe Bryant and the science of grief

By Market Analyst
January 28, 2020
China Coronavirus Vaccine
Newsletters

The hunt for a coronavirus vaccine begins

By Industry Analyst
January 24, 2020
American Well CEO Telehealth
Newsletters

Exclusive: American Well’s next act is turning your bedroom into a hospital

By Editorial Team
January 23, 2020
FDA Sarepta Drug Approval Controversy
Newsletters

Does the FDA need to slow its drug approval roll?

By Industry Analyst
January 22, 2020
China coronavirus U.S. case CDC
Newsletters

The CDC says the deadly coronavirus from China has now come to the U.S.

By Tech Reporter
January 22, 2020
Most Active States CDC
Newsletters

The most active states in America

By Trading Desk
January 17, 2020
Fitbit Flu Study
Newsletters

Could Fitbit be a flu warning tool?

By Industry Analyst
January 17, 2020
Coins2Day Brainstorm Updates
Newsletters

Changes are abound. Here’s what you should know

By Industry Analyst
January 16, 2020

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Blockchain Reporter
  • Economy
    One of the world’s most popular economists on why AI is ‘undoubtedly going to crash’: It’s built off ‘digital...
    By Market Analyst
  • Economy
    Trump's retreats on tariffs have already wiped out $800 billion of expected deficit reduction, CBO estimates
    By Financial Writer
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.